In order to extend the therapeutic potential of PARP inhibitors in cancer treatment, we explored predictive biomarkers for the PARP inhibitor treatment in ovarian cancers and found that NADP+ is an endogenous inhibitor of ADP-ribosylation. Here, PARP1 is linked to cancer.